More Evidence for the “Forgotten Valve.” Results from the TriValve Registry

Transcatheter tricuspid valve replacement is feasible with different devices, with a reasonable procedural success rate, and is associated with low peri-procedural mortality and significant clinical improvement. Mid-term survival was favorable in this high-risk population.

Más coincidencias de las esperadas entre válvulas bicúspides y tricúspidesGreater leaflet coaptation depth was associated with reduced procedural success, which, unsurprisingly, turned out to be an independent predictor of mortality.

 

The TriValve international registry was developed to assess the clinical usefulness of the initial application of transcatheter tricuspid valve replacement with different devices in patients with severe and symptomatic tricuspid regurgitation and high surgical risk.


Read also: New Light on the ‘Forsaken Valve’.


This registry included 312 high-risk patients (76.4 ± 8.5 years of age; 57% female; EuroSCORE II 9 ± 8%) at 18 centers. Interventions included repair at the leaflet level (MitraClip or PASCAL), annulus repair (Cardioband, TriCinch, and Trialign), or coaptation (FORMA) and replacement (caval implants, NaviGate, etc.).

 

More than one third of patients had prior intervention on a valve (whether surgical or transcatheter). Regurgitation etiology was functional in 93% of patients and mean annular diameter was 46.9 ± 9 mm; additionally, in most patients, the regurgitant jet was central (vena contracta 1.1 ± 0.5; effective regurgitant orifice area 0.78 ± 0.6 cm2). Pre-procedural systolic pulmonary artery pressure was high, with mean systolic pulmonary pressure 41 ± 14.8 mmHg.

 

The device most frequently used was MitraClip, with 210 cases, followed by all other devices with an average of 15-20 devices each.


Read also: TCT 2017 | The TRI-REPAIR and the FORMA Trials: New Devices for the “Forgotten Valve”.


Procedural success (defined as residual regurgitation ≤2+) was achieved in 72.8% of cases. Greater coaptation depth was an independent predictor of procedural failure (p = 0.002).

 

Thirty-day overall mortality was 3.6%; however, there was a significant difference between patients with and without procedural success (1.9% vs. 6.9%; p = 0.04).

 

Original title: Outcomes After Current Transcatheter Tricuspid Valve Intervention. Mid-Term Results from the International TriValve Registry.

Reference: Maurizio Taramasso et al. J Am Coll Cardiol Intv 2019. Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...